BRÈVE

sur Zentek Ltd. (NASDAQ:ZTEK)

Zentek Granted Second Patent from the Canadian Intellectual Patent Office

Graphique de l'évolution du cours de l'action Zentek Ltd. (EBR:ZTEK).

Zentek Ltd. has secured a second patent from the Canadian Intellectual Property Office for its Graphene Oxide-Cationic Silver (GO-Ag+) Nanocomposites. The patent, encompassing 64 claims, positions GO-Ag+ as a broad-spectrum antimicrobial agent effective against bacteria, fungi, and viruses. This follows an additional application with the United States Patent and Trademark Office. The IP covers liquid, powder, and ointments utilizing GO-Ag+.

Zentek collaborates with the University of Guelph on ongoing research. Previous findings showed GO-Ag+ has higher cytotoxicity on bacteria than human epithelial cells. Current studies aim at GO-Ag+'s efficacy in combating biofilms, a significant issue in wound care and medical devices, supporting future product developments for medical and veterinary markets.

Greg Fenton, CEO, regards this patent as essential for enhancing the IP commercialization strategy. The securement of this patent enables potential therapeutic applications in human and veterinary medicine, steering Zentek to explore ways to maximize shareholder value from this development.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Zentek Ltd.